MODERN APPROACHES AND RECENT ADVANCES IN NEUROENDOCRINE TUMORS

Modern Approaches and Recent Advances in Neuroendocrine Tumors-kapak

SYSTEMIC THERAPIES IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

Emre Hafızoğlu1 Teoman Şakalar2

1Afyonkarahisar State Hospital, Department of Medical Oncology, Afyonkarahisar, Türkiye
2Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Department of Medical Oncology, Kahramanmaraş, Türkiye

Hafızoğlu E, Şakalar T. Systemic Therapies in Gastroenteropancreatic Neuroendocrine Tumors. In: Gönüllü E, Karaman K, editors. Modern Approaches and Recent Advances in Neuroendocrine Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.183-189.

ABSTRACT

Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are classified as well-differentiated neuroendocrine tumors or poorly differentiated neuroendocrine carcinomas according to the Ki67 index. GEP-NET is a highly heterogeneous tumor group, and prognosis may vary according to a number of factors, including metastasis status, disease volume, organ of origin, localization, and degree of differentiation. In case of unresectable and metastatic disease, it is necessary to give patients systemic treatments to prolong overall survival and progression-free survival. These alternatives comprise somatostatin analogues, targeted treatments like everolimus and sunitinib, cytotoxic chemotherapies, peptide receptor radionuclide therapy (PRRT), and immunotherapy. We will discuss current systemic treatment approaches in this section.

Keywords: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs); Treatment; Lanreotide; Octreotide; Everolimus; Sunitinib; Chemotherapy

Referanslar

  1. Zhang XB, Fan YB, Jing R, Getu MA, Chen WY, Zhang W, et al. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives. Mil Med Res. 2024;11(1):35. [Crossref]  [PubMed]  [PMC]
  2. Passhak M, McNamara MG, Hubner RA, Ben-Aharon I, Valle JW. Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence? Best Pract Res Clin Endocrinol Metab. 2023;37(5):101836. [Crossref]  [PubMed]
  3. Sedlack AJH, Varghese DG, Naimian A, Yazdian Anari P, Bodei L, Hallet J, et al. Update in the management of gastroenteropancreatic neuroendocrine tumors. Cancer. 2024;130(18):3090-3105. [Crossref]  [PubMed]
  4. Mazziotti G, Mosca A, Frara S, Vitale G, Giustina A. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opin Pharmacotherapy. 2017;18:1679-89. [Crossref]  [PubMed]
  5. Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol. 2021;51(8):1185-1196. [Crossref]  [PubMed]  [PMC]
  6. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86(6):2779-86. [Crossref]  [PubMed]
  7. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, et al. Four year treatment with octreotide-long-act ing repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin EndocrinolMetab. 2003;90(7):3090-8. [Crossref]  [PubMed]
  8. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Orthod. 2009;27(28):4656-4663. [Crossref]  [PubMed]
  9. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233. [Crossref]  [PubMed]
  10. La Salvia A, Modica R, Rossi RE, Spada F, Rinzivillo M, Panzuto F, et al. Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from net specialists. Cancer Treat Rev. 2023;117:102560. [Crossref]  [PubMed]
  11. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844-860. [Crossref]  [PubMed]
  12. Rivero JD, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: asco guideline. J Clin Oncol. 2023;41:5049-67. [Crossref]  [PubMed]
  13. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, et al. The north american neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49:863-81. [Crossref]  [PubMed]
  14. Boerlin V, van der Hoek J, Beglinger Ch, Poon KW, Hartmann S, Dutreix C, et al. New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest. 2003;26(8 Suppl):14-6 gov/15233205 [Link]
  15. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875884. [Crossref]  [PubMed]
  16. Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075-86. [Crossref]  [PubMed]  [PMC]
  17. Vitale G, Dicitore A, Sciammarella C, Di Molfetta S, Rubino M, Faggiano A, et al. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. Endocr Relat Cancer. 2018;25(6):R351-R364. [Crossref]  [PubMed]
  18. Grillo F, Florio T, Ferraù F, Kara E, Fanciulli G, Faggiano A, et al. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocr Relat Cancer. 2018;25(9):R453-R466. [Crossref]  [PubMed]
  19. Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, et al. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2018;107(3):237-245. [Crossref]  [PubMed]
  20. Chan, J, Geyer S, Ou FS, Knopp M, Behr S, Zemla T, et al. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Annals of Oncology, 34, S1292. [Crossref]
  21. Bergsland EK, Mahoney MR, Asmis TR, Hall N, Kumthekar P, Maitland ML, et al. Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC)(AllianceA021202).
  22. Bongiovanni A, Liverani C, Recine F, Fausti V, Mercatali L, Vagheggini A, et al. Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis. Front Oncol. 2020;10:414. [Crossref]  [PubMed]  [PMC]
  23. Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, García-Carbonero R, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer. 2013;49(18):3780-7. [Crossref]  [PubMed]
  24. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, et al. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016;23(5):411-8. [Crossref]  [PubMed]  [PMC]
  25. Bertolini F, Marighetti P, Martin-Padura I, Mancuso P, HuLowe DD, Shaked Y, et al. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov Today. 2011;16(23-24):1052-60. [Crossref]  [PubMed]
  26. Xu J, Shen L, Bai C, Wang W, Li J, Yu X, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1489-1499. [Crossref]  [PubMed]
  27. Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1500-1512. [Crossref]
  28. Koumarianou A, Kaltsas G. Surufatinib a novel oral agent for neuroendocrine tumours. Nat Rev Endocrinol. 2021;17(1):9-10. [Crossref]  [PubMed]
  29. Crabtree JS. Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Front Endocrinol (Lausanne). 2017;8:341. [Crossref]  [PubMed]  [PMC]
  30. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011 Feb 2;305(5):487-94. [Crossref]  [PubMed]
  31. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome: a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005-12. [Crossref]  [PubMed]
  32. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract: a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968-77. [Crossref]  [PubMed]
  33. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-23. [Crossref]  [PubMed]  [PMC]
  34. Pavel M, O'Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172-185. [Crossref]  [PubMed]
  35. Medley L, Morel AN, Farrugia D, et al. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer. 2011;104(7):1067-1070. [Crossref]  [PubMed]  [PMC]
  36. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23(22):4897-4904. [Crossref]  [PubMed]
  37. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15(1):338. [Crossref]  [PubMed]  [PMC]
  38. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268-275. [Crossref]  [PubMed]  [PMC]
  39. Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663-670. [Crossref]  [PubMed]
  40. Chan DL, Bergsland EK, Chan JA, et al. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. Oncologist. 2021;26(11):950-955. [Crossref]  [PubMed]  [PMC]
  41. Liu AJ, Ueberroth BE, McGarrah PW, et al. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. Oncologist. 2021;26(5):383-388. [Crossref]  [PubMed]  [PMC]
  42. Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, et al. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. CEPD investigators Eur J Cancer. 2017;79:158. Epub 2017 May 11. [Crossref]  [PubMed]
  43. Hadoux J, Malka D, Planchard D, et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015;22(3):289-298. [Crossref]  [PubMed]
  44. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152-60. Epub 2012 Sep 11. [Crossref]  [PubMed]